SPY411.49+2.97 0.73%
DIA337.86+2.73 0.81%
IXIC13,900.19+70.88 0.51%

Codiak BioSciences: On Track to Report Biomarker, Safety and Clinical Anti-Tumor Efficacy Results in Cancer Patients in Mid-2021 for exoSTING and by Yr-end for ExoIL-12 >CDAK

Codiak BioSciences: On Track to Report Biomarker, Safety and Clinical Anti-Tumor Efficacy Results in Cancer Patients in Mid-2021 for exoSTING and by Yr-end for ExoIL-12 >CDAK

· 03/17/2021 07:38

Please log in to view news